Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 63 of the 63 references it cites were found in a registry or an index; 35 of the 75 sources its claims cite were checked for support.

Subcutaneously administered tirzepatide vs semaglutide for adults with type 2 diabetes: a systematic review and network meta-analysis of randomised controlled trials

Open access

Abstract

Aims/hypothesis: We conducted a systematic review and network meta-analysis to compare the efficacy and safety of s.c. administered tirzepatide vs s.c. administered semaglutide for adults of both sexes with type 2 diabetes mellitus. Methods: We searched PubMed and Cochrane up to 11 November 2023 for RCTs with an intervention duration of at least 12 weeks assessing s.c. tirzepatide at maintenance doses of 5 mg, 10 mg or 15 mg once weekly, or s.c. semaglutide at maintenance doses of 0.5 mg, 1.0 mg or 2.0 mg once weekly, in adults with type 2 diabetes, regardless of background glucose-lowering treatment. Eligible trials compared any of the specified doses of tirzepatide and semaglutide against each other, placebo or other glucose-lowering drugs. Primary outcomes were changes in HbA 1c and body weight from baseline. Secondary outcomes were achievement of HbA 1c target of ≤48 mmol/mol (≤6.5%) or <53 mmol/mol (<7.0%), body weight loss of at least 10%, and safety outcomes including gastrointestinal adverse events and severe hypoglycaemia. We used version 2 of the Cochrane risk-of-bias tool (ROB 2) to assess the risk of bias, conducted frequentist random-effects network meta-analyses and evaluated confidence in effect estimates utilising the Confidence In Network Meta-Analysis (CINeMA) framework. Results: A total of 28 trials with 23,622 participants (44.2% female) were included. Compared with placebo, tirzepatide 15 mg was the most efficacious treatment in reducing HbA 1c (mean difference −21.61 mmol/mol [−1.96%]) followed by tirzepatide 10 mg (−20.19 mmol/mol [−1.84%]), semaglutide 2.0 mg (−17.74 mmol/mol [−1.59%]), tirzepatide 5 mg (−17.60 mmol/mol [−1.60%]), semaglutide 1.0 mg (−15.25 mmol/mol [−1.39%]) and semaglutide 0.5 mg (−12.00 mmol/mol [−1.09%]). In between-drug comparisons, all tirzepatide doses were comparable with semaglutide 2.0 mg and superior to semaglutide 1.0 mg and 0.5 mg. Compared with placebo, tirzepatide was more efficacious than semaglutide for reducing body weight, with reductions ranging from 9.57 kg (tirzepatide 15 mg) to 5.27 kg (tirzepatide 5 mg). Semaglutide had a less pronounced effect, with reductions ranging from 4.97 kg (semaglutide 2.0 mg) to 2.52 kg (semaglutide 0.5 mg). In between-drug comparisons, tirzepatide 15 mg, 10 mg and 5 mg demonstrated greater efficacy than semaglutide 2.0 mg, 1.0 mg and 0.5 mg, respectively. Both drugs increased incidence of gastrointestinal adverse events compared with placebo, while neither tirzepatide nor semaglutide increased the risk of serious adverse events or severe hypoglycaemia. Conclusions/interpretation: Our data show that s.c. tirzepatide had a more pronounced effect on HbA 1c and weight reduction compared with s.c. semaglutide in people with type 2 diabetes. Both drugs, particularly higher doses of tirzepatide, increased gastrointestinal adverse events. Registration: PROSPERO registration no. CRD42022382594 Graphical Abstract:

Overview

CoChat Summary

TL;DR

This systematic review and network meta-analysis of 28 RCTs (23,622 adults with type 2 diabetes) found that s.c. tirzepatide generally reduced HbA1c and body weight more than s.c. semaglutide, although all tirzepatide doses were comparable with semaglutide 2.0 mg for HbA1c when measured in mmol/mol. Both drugs increased gastrointestinal adverse events versus placebo, without increasing serious adverse events or severe hypoglycaemia.

Key findings

  • In 28 RCTs with 23,622 participants (44.2% female), tirzepatide 15 mg was the most efficacious treatment for HbA1c reduction versus placebo: −21.61 mmol/mol (−1.96%), followed by tirzepatide 10 mg (−20.19 mmol/mol; −1.84%), semaglutide 2.0 mg (−17.74 mmol/mol; −1.59%), tirzepatide 5 mg (−17.60 mmol/mol; −1.60%), semaglutide 1.0 mg (−15.25 mmol/mol; −1.39%) and semaglutide 0.5 mg (−12.00 mmol/mol; −1.09%).
  • For HbA1c, all tirzepatide doses were comparable with semaglutide 2.0 mg and superior to semaglutide 1.0 mg and 0.5 mg when HbA1c was measured in mmol/mol; when measured in %, tirzepatide 15 mg, 10 mg and 5 mg demonstrated greater efficacy than semaglutide 2.0 mg, 1.0 mg and 0.5 mg, respectively.
  • Versus placebo, body weight reductions ranged from 9.57 kg with tirzepatide 15 mg to 5.27 kg with tirzepatide 5 mg, and from 4.97 kg with semaglutide 2.0 mg to 2.52 kg with semaglutide 0.5 mg; between-drug comparisons showed tirzepatide 15 mg, 10 mg and 5 mg were more efficacious than semaglutide 2.0 mg, 1.0 mg and 0.5 mg, respectively (MD −4.60 kg, −3.53 kg and −2.75 kg).
  • Both drugs increased nausea, vomiting and diarrhoea versus placebo, and neither increased serious adverse events or severe hypoglycaemia; severe hypoglycaemia meta-analysis was not conducted because of absent events in most treatment arms.

Methods

  • Systematic review and network meta-analysis of RCTs published in English, searched in PubMed and Cochrane up to 11 November 2023, including adults with type 2 diabetes and interventions of at least 12 weeks with s.c. tirzepatide 5/10/15 mg or s.c. semaglutide 0.5/1.0/2.0 mg once weekly.
  • Eligible trials compared specified doses against each other, placebo or other glucose-lowering drugs that had been evaluated in at least one trial against tirzepatide and one against semaglutide; 28 trials with 23,622 participants were included.
  • Frequentist random-effects network meta-analyses estimated mean differences and risk ratios with 95% CIs; risk of bias was assessed with ROB 2, confidence with CINeMA, and treatments ranked using P-scores.

Limitations

  • Stated: the focused inclusion criteria are not well suited for evaluating the two medications versus common comparators; confidence was low for comparisons involving semaglutide 2.0 mg because only one RCT assessed this dose; five RCTs recruited exclusively Japanese participants, and no sex-based subgroup analyses were performed.
  • Stated: long-term cardiovascular or mortality outcomes were excluded a priori because SURPASS-CVOT was ongoing; HbA1c results varied by measurement unit, with mmol/mol analyses requiring imputations or borrowing of variance values; protocol deviations included not analysing ≥5% body weight reduction and not performing planned sensitivity or subgroup analyses.
  • Evident from the text: only two trials directly compared tirzepatide with semaglutide, so most comparative estimates rely on indirect evidence; 15 of the included trials were open-label.

Model-written summary. Check it against the paper before relying on it.

Integrity signals

Registry

Crossref · 10.1007/s00125-024-06144-1

Cites

63 of 63 references verified0 citation errors · 0 not checkable

Statistics

Nothing to recompute.

Figures

Fig. 1 Network plot for change in HbA1c. Each circle indicates a treatment node. Lines connecting two nodes represent direct comparisons between two treatments. The size of the nodes is proportional to the number of trials evaluating each treatment; the thickness of the lines is proportional to the number of trials directly comparing the two connected treatments
Fig. 1 Network plot for change in HbA1c. Each circle indicates a treatment node. Lines connecting two nodes represent direct comparisons between two treatments. The size of the nodes is proportional to the number of trials evaluating each treatment; the thickness of the lines is proportional to the number of trials directly comparing the two connected treatmentsCC BY · PubMed Central
Fig. 2 Network meta-analysis results for the change in HbA1c (mmol/mol) compared with placebo
Fig. 2 Network meta-analysis results for the change in HbA1c (mmol/mol) compared with placeboCC BY · PubMed Central
Fig. 3 Network meta-analysis results for the change in body weight (kg) compared with placebo
Fig. 3 Network meta-analysis results for the change in body weight (kg) compared with placeboCC BY · PubMed Central
Fig. 4 Network meta-analysis results for the discontinuation of treatment due to gastrointestinal adverse events compared with placebo. RR, risk ratio
Fig. 4 Network meta-analysis results for the discontinuation of treatment due to gastrointestinal adverse events compared with placebo. RR, risk ratioCC BY · PubMed Central

Verification

Claims the paper makes

28 Valid · 1 Not valid · 26 Not checked · 58 Own results and interpretations

53 more claims · 4 with their cited sources checked

Create a free account to see all 113 claims and to verify the 2 references still open.

See all claims — free account
  • Probably not a substantial claim. 31
  • It may state two separate claims as one. 34

Create a free account to see these claims.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

Each contradiction between two passages listed here was confirmed by an independent check.

1 of 1

Citations

Cites

Show all 62 references

Cited by

See all 102

Metadata

Authors
Karagiannis, T., Malandris, K., Avgerinos, I., Stamati, A., Kakotrichi, P., Liakos, A., Vasilakou, D., Kakaletsis, N., Tsapas, A., & Bekiari, E.
Affiliations
Aristotle University of Thessaloniki (GR)
Corresponding author
Karagiannis, Thomas
Venue
Diabetologia
Published
2024-04-13
Volume
67
Issue
7
Pages
1206-1222
ISSN
  • 0012-186X (ISSN-L)
  • 1432-0428
OpenAlex
W4394785699
Cited by
102
References
62
Citations by year
2026: 27 · 2025: 62 · 2024: 13
FWCI
5.95
Type
journal article
Language
en
Open access
Licence
Locations
  • Diabetologia (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
Funders
Aristotle University of Thessaloniki
Topics
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
  • Health Sciences › Medicine › Pharmacology (medical) › Pharmacology and Obesity Treatment
Keywords
tirzepatide, semaglutide, type 2 diabetes, HbA1c, weight loss, gastrointestinal adverse effects, severe hypoglycemia, GLP-1 receptor agonists, antidiabetic drugs, drug efficacy and safety comparison, subcutaneous administration
MeSH terms
Glucagon-Like Peptide-2 Receptor, Tirzepatide, Semaglutide, Adult, Blood Glucose, Diabetes Mellitus, Type 2, Glucagon-Like Peptides, Female, Gastric Inhibitory Polypeptide, Glycated Hemoglobin, Humans, Hypoglycemic Agents, Injections, Subcutaneous, Male, Randomized Controlled Trials as Topic

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

The claim verdicts this report counts are experimental: their accuracy is not yet measured.

A language model drew the claims from the paper on 2026-10-29, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).

A second model labelled each claim on 2026-10-29 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).

Cited sources are checked with a language model’s help (gpt-6-sol).

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Subcutaneously administered tirzepatide vs semaglutide for adults with type 2 diabetes: a systematic review and network meta-analysis of randomised controlled trials. https://app.cochat.ai/papers/10.1007/s00125-024-06144-1
The paper
Karagiannis, T., Malandris, K., Avgerinos, I., Stamati, A., Kakotrichi, P., Liakos, A., Vasilakou, D., Kakaletsis, N., Tsapas, A., & Bekiari, E. (2024). Subcutaneously administered tirzepatide vs semaglutide for adults with type 2 diabetes: a systematic review and network meta-analysis of randomised controlled trials. Diabetologia. https://doi.org/10.1007/s00125-024-06144-1

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.